ALZYN Announces Promising Preclinical Results for Alzheimer’s Therapy

Share Article

ALZYN, LLC, announces today that their developmental product crossed through the skin and permeated the blood-brain barrier in independent preclinical testing on rats. This represents a major developmental milestone

We are very pleased that our radical, new approach to potentially slowing the progress of Alzheimer’s has passed through this critical gate.

ALZYN LLC (, a development stage company pursuing a unique approach to retarding the progress of Alzheimer's Disease employing naturally occurring compounds announced today that in preclinical testing on rats, their transdermal developmental product, EKD-2, was successful in crossing the skin and reaching the brain. This represents a major developmental milestone. “We are very pleased that our radical, new approach to potentially slowing the progress of Alzheimer’s has passed through this critical gate. EKD-2 may offer a beacon of hope where there currently is none”.” said Don Rosenkoetter, Co-Founder and President of ALZYN.

Ewa Bienkiewicz, PhD, Biomedical Sciences Research Associate Professor at the Florida State University’s College of Medicine, established that a combination of four naturally occurring compounds has marked ability to beneficially support the body’s response to several factors associated with the causes and progression of Alzheimer’s (Beesley, Olcese, Saunders, & Bienkiewicz, Journal of Alzheimer’s Disease 55 (2017) 1155–1166).

ALZYN has an exclusive license from the Florida State University Research Foundation for Dr. Bienkiewicz’s science and has partnered with TD Solutions Corp (TDSC) to couple TDSC’s HypoSpray® technology, a unique transdermal delivery system, with the four compounds to create a novel method to get these compounds to where they are needed: the brain.

A core developmental challenge was to get the formulation components to the brain, circumventing their mal-absorption in the gut. The HypoSpray® technology, because it is transdermally applied, bypasses the digestive tract and enables raising effective dose levels of compounds like the EKD-2 actives.

About ALZYN, LLC                                             
ALZYN is a development stage company committed to reducing the tragedy of Alzheimer's. The Company is pursuing a unique and promising approach to altering the progression of Alzheimer’s. The science, licensed from the Florida State Research Foundation, is at a preclinical development stage.

Contact Information:
Name: Don Rosenkoetter, Co-Founder and President
Email: gdr(at)alzyn(dot)com
Address: 2401 2nd Street N., St. Petersburg, FL 33704
Telephone: 617.461.6654

About TD Solutions (TDSC)                                

TD Solutions is committed to advancing the science of transdermal drug delivery using its patented spray-on delivery system, HypoSpray®. TDSC’s proprietary system enables medications to be delivered directly through the skin, for systemic or localized application, utilizing its rapid acting, patchless, spray-on technology. The company’s technology is flexible enough to be applicable to a very wide range of compounds up to small peptides for pharmaceutical or cosmetic use. No other company can offer similar, consumer friendly, dosing flexible solutions.
Company: TD Solutions Corp.:

Contact Information:
Name: Cindy Metzler, MarCom Consultant (for TDSC)
Email: cindy(at)cindymetzler(dot)com
Address: 11000 Prosperity Farms Road, Palm Beach Gardens, FL 33410
Telephone: 561.429.6429 (Headquarters)

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Evans

Don Rosenkoetter, Co-Founder and President
Visit website